Posted October 9, 2020
U.S. pharmaceutical and medical devices company Johnson & Johnson, Inc. announced the start of the Phase 3 human clinical trial for its experimental Ad26.COV2.S vaccine for COVID-19. The New Jersey-based company, which is partnering with its subsidiary Janssen Pharmaceutica NV of Belgium on development of the vaccine, is planning to enroll 60,000 volunteers to participate in the trial. Read more.